Chest:COPD患者的心血管风险

2019-11-22 xing.T MedSci原创

由此可见,对未选择的原因不同的COPD患者分析表明:1)COPD本身不足以解释其增加aPWV,2)吸烟是COPD患者aPWV增加的危险因素。

慢性阻塞性肺疾病(COPD)是心血管疾病(CVD)的独立危险因素,这一发现来自对患有COPD的吸烟者和未患有COPD的吸烟者进行比较。尚不清楚COPD患者CVD风险增加的机制。近日,呼吸领域权威杂志chest上发表了一篇研究文章,该研究旨在评估系统性动脉僵硬度(CVD死亡率的预测指标),并评估因有机粉尘暴露、吸烟或两者均有引起的轻度至中度COPD患者的决定因素。

研究人员通过主动脉脉搏波速度(aPWV)评估全身动脉僵硬度。对142名COPD患者和155名健康对照者进行了测量,并匹配了受试者年龄、性别、体重指数和吸烟、暴露于香烟(COPD/对照分别为=56/70)、有机粉尘(n=44/48)或两者兼有(n=42/37)。主

相比暴露于吸烟,烟尘和粉尘均有的健康对照者,COPD患者的PWV更高。相比之下,在接触有机粉尘的不吸烟者中,COPD患者和相匹配的对照者的aPWV相似。对142名COPD患者(暴露于吸烟和/或有机粉尘)的多变量分析表明,吸烟与高aPWV有关。此外,这些患者中主要心血管事件的标志物,可溶性致癌抑制因子2(ST2)与aPWV相关。

由此可见,对未选择的原因不同的COPD患者分析表明:1)COPD本身不足以解释其增加aPWV,2)吸烟是COPD患者aPWV增加的危险因素。 

原始出处:

Thibaud Soumagne,et al.Cardiovascular Risk in COPD: Deciphering the Contribution of Tobacco Smoking.chest.2019.https://doi.org/10.1016/j.chest.2019.11.002

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929592, encodeId=775b192959291, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed May 06 16:41:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051465, encodeId=f08e20514655d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 02 21:41:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082518, encodeId=8d6d2082518b5, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jan 28 05:41:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375801, encodeId=5b653e58014e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Nov 25 06:08:14 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488848, encodeId=6c821488848e6, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Sun Nov 24 04:41:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
    2020-05-06 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929592, encodeId=775b192959291, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed May 06 16:41:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051465, encodeId=f08e20514655d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 02 21:41:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082518, encodeId=8d6d2082518b5, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jan 28 05:41:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375801, encodeId=5b653e58014e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Nov 25 06:08:14 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488848, encodeId=6c821488848e6, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Sun Nov 24 04:41:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929592, encodeId=775b192959291, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed May 06 16:41:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051465, encodeId=f08e20514655d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 02 21:41:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082518, encodeId=8d6d2082518b5, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jan 28 05:41:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375801, encodeId=5b653e58014e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Nov 25 06:08:14 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488848, encodeId=6c821488848e6, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Sun Nov 24 04:41:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929592, encodeId=775b192959291, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed May 06 16:41:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051465, encodeId=f08e20514655d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 02 21:41:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082518, encodeId=8d6d2082518b5, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jan 28 05:41:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375801, encodeId=5b653e58014e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Nov 25 06:08:14 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488848, encodeId=6c821488848e6, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Sun Nov 24 04:41:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
    2019-11-25 thm112988

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1929592, encodeId=775b192959291, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed May 06 16:41:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051465, encodeId=f08e20514655d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 02 21:41:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082518, encodeId=8d6d2082518b5, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jan 28 05:41:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375801, encodeId=5b653e58014e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Nov 25 06:08:14 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488848, encodeId=6c821488848e6, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Sun Nov 24 04:41:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
    2019-11-24 gous

相关威廉亚洲官网

NEJM:Benralizumab预防COPD恶化

在研究发现,在中重度慢性阻塞性肺病患者中,与安慰剂相比,Benralizumab可降低慢性阻塞性肺病年化恶化率

JAMA:院外自我管理对COPD患者预后无益

3个月的COPD自我管理计划导致患者住院及急诊事件增加,并且对患者生活质量无改善作用。

BMJ:慢性阻塞性肺病患者预后预测模型

本研究对COPD患者预后模型进行了详细评估。调查结果表明,大部分在发展过程中存在若干方法上的缺陷,外部验证率较低

NEJM:美托洛尔不能预防COPD患者加重恶化

在中度或重度慢性阻塞性肺病患者中,美托洛尔无法降低慢性阻塞性肺病患者的第一次加重恶化风险

2019年ERS:阿奇霉素持续治疗可降低重度COPD患者加重的频率

根据2019年欧洲呼吸学会(ERS)国际大会上发表的一项研究,患有频繁加重的严重慢性阻塞性肺疾病(COPD)患者连续使用阿奇霉素治疗可改善对加重的控制。

Lancet respir med:嗜酸性粒细胞计数高的COPD患者可获得较好的Benralizumab治疗效果

Benralizumab治疗对血液嗜酸性粒细胞计数升高COPD人群具有较好的治疗效果